Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles

SIGNIFICANCE AND USE
5.1 This test method is one of a series of tests listed in Practice F748 and ISO 10993-4 to assess the biocompatibility of materials contacting blood in medical applications.  
5.2 This test method is similar to Practice F756 but modified to accommodate nanoparticulate materials.
SCOPE
1.1 This test method covers assessing the effect of nanoparticulate materials on the integrity of red blood cells.  
1.2 This test method uses diluted whole blood incubated with nanoparticulate material and the hemoglobin released from damaged red blood cells is determined.  
1.3 This test method is similar to Practice F756 with the volumes reduced to accommodate nanoparticulate material.  
1.4 This test method is part of the in-vitro preclinical characterization and is important for nanoparticulate material that will contact the blood in medical applications.  
1.5 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.  
1.6 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.  
1.7 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

General Information

Status
Published
Publication Date
31-Aug-2022
Current Stage
Ref Project

Buy Standard

Standard
ASTM E2524-22 - Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles
English language
6 pages
sale 15% off
Preview
sale 15% off
Preview

Standards Content (Sample)

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the
Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
Designation: E2524 − 22
Standard Test Method for
1
Analysis of Hemolytic Properties of Nanoparticles
This standard is issued under the fixed designation E2524; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision.Anumber in parentheses indicates the year of last reapproval.A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope F1877Practice for Characterization of Particles
F1903Practice for Testing for Cellular Responses to Par-
1.1 This test method covers assessing the effect of nanopar-
ticles in vitro
ticulate materials on the integrity of red blood cells.
3
2.2 ISO Standard:
1.2 This test method uses diluted whole blood incubated
ISO 10993-4Biological Evaluation of Medical Devices Part
with nanoparticulate material and the hemoglobin released
4: Selection of Tests for Interactions with Blood
from damaged red blood cells is determined.
3. Terminology
1.3 This test method is similar to Practice F756 with the
volumes reduced to accommodate nanoparticulate material.
3.1 Acronyms:
3.1.1 Cal—calibration standard
1.4 This test method is part of the in-vitro preclinical
characterization and is important for nanoparticulate material
3.1.2 CMH—cyanmethemoglobin
that will contact the blood in medical applications.
3.1.3 DPBS—Dulbecco’s phosphate-buffered saline
1.5 The values stated in SI units are to be regarded as
3.1.4 PFH—plasma-free hemoglobin
standard. No other units of measurement are included in this
3.1.5 QC—quality controls
standard.
3.1.6 TBH—total blood hemoglobin
1.6 This standard does not purport to address all of the
3.1.7 TBHd—blood sample diluted to 10 mg 6 1 mg/mL
safety concerns, if any, associated with its use. It is the
responsibility of the user of this standard to establish appro-
4. Summary of Test Method
priate safety, health, and environmental practices and deter-
mine the applicability of regulatory limitations prior to use.
4.1 Thistestmethoddescribesaprotocolforassessingacute
1.7 This international standard was developed in accor-
in-vitro damage to red blood cells (that is, hemolysis) caused
dance with internationally recognized principles on standard-
by exposure to nanoparticles.
ization established in the Decision on Principles for the
4.2 This test method is based on the quantitative determi-
Development of International Standards, Guides and Recom-
nation of hemoglobin released into PFH as a percentage of the
mendations issued by the World Trade Organization Technical
TBH concentration when blood is exposed to nanoparticulate
Barriers to Trade (TBT) Committee.
materials.
4
2. Referenced Documents
4.3 Using an established colorimetric assay, hemoglobin
2
and its derivatives, such as sulfhemoglobin, are oxidized to
2.1 ASTM Standards:
methemoglobin by ferricyanide in the presence of alkali. A
F748PracticeforSelectingGenericBiologicalTestMethods
stable CMH concentration is measured using a plate reader
for Materials and Devices
spectrophotometer set at 540 nm.
F756Practice for Assessment of Hemolytic Properties of
Materials
4.4 Hemoglobin standards are used to create a standard
curvecoveringtherangefrom0.025mg⁄mLto0.8mg/mLand
prepare quality control samples at low (0.0625-mg/mL), mid
1
This test method is under the jurisdiction of ASTM Committee E56 on
(0.125-mg/mL), and high (0.625-mg/mL) concentrations to
Nanotechnology and is the direct responsibility of Subcommittee E56.03 on
Environment, Health, and Safety.
monitor assay performance. The required sample volume is
Current edition approved Sept. 1, 2022. Published October 2022. Originally
100 µL per test replicate.
approved in 2008. Last previous edition approved in 2013 as E2524 – 08(2013),
which was withdrawn in April 2022 and reinstated in September 2022. DOI:
10.1520/E2524-22.
2 3
For referenced ASTM standards, visit the ASTM website, www.astm.org, or Available fromAmerican National Standards Institute (ANSI), 25 W. 43rd St.,
contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM 4th Floor, New York, NY 10036, http://www.ansi.org.
4
Standards volume information, refer to the standard’s Document Summary page on International Committee for Standardization in Haemotology, Journal of
the ASTM website. Clinical Pathology, Vol 31, 1978, pp. 139–143.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1

---------------------- Page: 1 ----------------------
E2524 − 22
TABLE 2 Quality Controls
4.5 The results are expressed as percent hemolysis to
evaluate the acute in-vitro hemolytic properties of
...

Questions, Comments and Discussion

Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.